Evidence map›Paper›PMID 25416859›Full record

SynthesisMolecular neurobiology2016

Serum MicroRNA-125b as a Potential Biomarker for Glioma Diagnosis.

XiangTai Wei, Duo Chen, Tao Lv, Gang Li, ShengTao Qu

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Molecular neurobiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 5 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 5 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Article
  8. MicroRNAs as Biomarkers of Brain Tumor.Cancer management and research · 2024
    Review
  9. Cell-Free miRNAs as Non-Invasive Biomarkers in Brain Tumors.Diagnostics (Basel, Switzerland) · 2023
    Review
  10. Article
  11. Review
  12. Review
  13. Circulating MicroRNAs as Cancer Biomarkers in Liquid Biopsies.Advances in experimental medicine and biology · 2022
    Review
  14. Review
  15. Prognostic and Predictive Biomarkers in Gliomas.International journal of molecular sciences · 2021
    Review
  16. Molecular and Circulating Biomarkers of Brain Tumors.International journal of molecular sciences · 2021
    Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

XiangTai WeiDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, 110004, China. weixiangtai@yeah.net.
Duo ChenDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Tao LvDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Gang LiDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
ShengTao QuDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biomarkers in blood have become increasingly appreciated in the diagnosis of glioma, but most of their diagnostic accuracy was not high enough to be used widely in a clinical context. MicroRNA-125b (miRNA-125b, miR-125b), a member of microRNA cluster, is widely considered as ideal biomarkers for clinical diagnosis in various human cancers. In the current study, we first explored the diagnostic value of serum miR-125b for glioma in a Chinese population, which has not been studied yet. Additionally, we conducted a meta-analysis to assess the diagnostic accuracy of miR-125b in human cancers. Serum miR-125b from the 33 patients with glioma (WHO grades I-IV) and 33 healthy controls were compared. Our results showed that the serum miR-125b level was significantly lower in glioma patients when compared with normal population, and an obvious decreasing trend of miR-125b level along tumor stages was found. The receiver operating characteristic (ROC) curve analysis of the accuracy in distinguishing glioma cancer patients from healthy controls yielded an area under the curve (AUC) value of 0.839 (95 % confidence interval (CI), 0.743-0.935). When glioma patients at different stages were compared with normal controls, the AUC values of WHO grade II (0.868) and WHO grade III-IV (0.959) were higher than WHO grade I (0.691). In the meta-analysis, the overall sensitivity, specificity, and AUC for miR-125b in human cancers diagnosis were 82 % (95 % CI, 76-87 %), 77 % (95 % CI, 70-84 %), and 0.84 (95 % CI, 0.81-0.87), respectively. The results of the present study suggested that miR-125b could be a potential biomarker with relatively high accuracy in the diagnosis of glioma as well as other human cancers.

Indexed as

AdultBiomarkers, TumorFemaleGliomaHumansMaleMicroRNAsMiddle AgedPrognosisROC CurveSensitivity and SpecificityBiomarkers, TumorMicroRNAsMIRN125 microRNA, humanBiomarkerDiagnosisGliomaMeta-analysisMicroRNA-125bSerum

Identifiers

PMID25416859
OpenAlexW2032967049

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.